NASDAQ: FORAForian Inc Stock
$2.02-0.14 (-6.48%)
Updated Apr 30, 2025
FORA Price
$2.02
Fair Value Price
N/A
Market Cap
$63.01M
52 Week Low
$1.85
52 Week High
$4.03
P/E
-16.83x
P/B
2.1x
P/S
3.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.15M
Earnings
-$3.77M
Gross Margin
63.6%
Operating Margin
-14.86%
Profit Margin
-18.7%
Debt to Equity
0.57
Operating Cash Flow
$283k
Beta
0.54
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FORA Overview
Forian Inc. provides software solutions, proprietary data-driven insights, and predictive analytics to the healthcare, cannabis, and government sectors. The company's products include BioTrack, Cannalytics, BioTrack State Traceability & Enforcement Monitoring System, and STEMS. The company also offers security monitoring and web marketing services. The company is headquartered in Newtown, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FORA's potential to beat the market
- FORA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
FORA
RankedUnranked of 45
RankedUnranked of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $109.97 | A | |
| $26.03 | A | |
| $4.63 | B |
Be the first to know about important FORA news, forecast changes, insider trades & much more!
FORA News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FORA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FORA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FORA is good value based on its book value relative to its share price (2.1x), compared to the US Health Information Services industry average (3.52x)
P/B vs Industry Valuation
FORA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FORA due diligence checks available for Premium users.
Valuation
FORA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.83x
Industry
40.3x
Market
29.18x
FORA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.1x
Industry
3.52x
FORA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FORA's financial health
Profit margin
Revenue
$5.8M
Net Income
$199.7k
Profit Margin
3.4%
FORA's Earnings (EBIT) of -$3.00M... subscribe to Premium to read more.
Interest Coverage Financials
FORA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$47.2M
Liabilities
$17.1M
Debt to equity
0.57
FORA's short-term assets ($44.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FORA's short-term assets ($44.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FORA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FORA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.7M
Investing
$18.0M
Financing
-$17.9M
FORA's operating cash flow ($282.83k)... subscribe to Premium to read more.
Debt Coverage Financials
FORA vs Health Information Service Stocks
Forian Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.